No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Healthcare Information Services
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
www.artrya.comNo one on the platform currently holds AYA.AX.
No tracked institution reports a position in AYA.AX as of their last filing.
No one on the platform has traded AYA.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 0.0% | |||||
| Profit Margin % | -89939.3% | |||||
| Free Cash Flow Margin % | -56828.6% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $5M | +50.4% | $-0.13 | $-0.14–$-0.12 | — | 2 |
| 2028 | $22M | +321.7% | $-0.08 | $-0.09–$-0.07 | — | 2 |
| 2029 | $50M | +122.8% | $0.05 | $0.02–$0.08 | — | 2 |
| 2030 | $85M | +70.8% | $0.08 | $0.07–$0.09 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-19 | $-0.05 | $-0.09 | -61.1% |
| 2024-08-29 | $-0.08 | $-0.00 | +99.9% |
| 2024-02-28 | $-0.10 | $-0.09 | +7.9% |
| 2023-02-21 | $-0.11 | $-0.08 | +25.1% |
| $144M |
| — |
| IMM.AXImmutep Limited | $0.04 | +0.00% | $66M | — |
| IMR.AXImricor Medical Systems, Inc. | $1.83 | -0.54% | $589M | — |
Source: Financial Modeling Prep · peers by sector/industry